Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06280950 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Expanding Liver Transplant Immunosuppression Minimization Via Everolimus

Study acronym: ELIMINATE
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 8 → 12 locations Eligibility criteria expanded, about 10 words · Secondary endpoints: details revised at 3 of 22 entries Show 2 more changesShow less
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: details revised at 3 of 22 entries
  2. Site contacts updated at 8 of 8 sitesv13
  3. Site contacts updated at 1 of 8 sitesv12
  4. Primary completion date: Jun 1, 2027 to Jun 30, 2028 Completion date: Jun 1, 2029 to Jun 30, 2030v11 Show 1 more changeShow less
    • Completion date: Jun 1, 2029 to Jun 30, 2030
  5. Eligibility criteria expanded, about 22 words Secondary endpoints revised (22) · Study description revisedv10 Show 2 more changesShow less
    • Secondary endpoints revised (22)
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

Show 8 earlier versionsHide 8 earlier versions
  1. Site details revised at 3 of 8 sitesv9
  2. Site details revised at 1 of 8 sitesv8
  3. Eligibility criteria expanded, about 1 wordv7 See this version in full on ClinicalTrials.gov ↗
  4. Site details revised at 1 of 8 sitesv6
  5. Start date changed from estimate of Aug 26, 2024 to Sep 12, 2024v5
  6. Trial status: Not Yet Recruiting to Recruiting Start date: Jul 31, 2024 to Aug 26, 2024 · Site details revised at 8 of 8 sitesv4 Show 2 more changesShow less
    • Start date: Jul 31, 2024 to Aug 26, 2024
    • Site details revised at 8 of 8 sites
  7. Start date: Jun 30, 2024 to Jul 31, 2024v3
  8. Start date: Mar 31, 2024 to Jun 30, 2024 Eligibility criteria revised · Study sites revised (8)v2 Show 2 more changesShow less
    • Eligibility criteria revised
    • Study sites revised (8)

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a study to determine the safety, efficacy, and tolerability of taking away the anti-rejection medicine, tacrolimus, in liver transplant recipients in conjunction with everolimus monotherapy to preserve renal function. Two hundred - seventy (270) subjects will be randomized 2:1 into one of two groups between 2-3 months post-transplant. Seventy participants will be placed into an observational group and will remain on their current post-transplant medications. The duration of the study from time of enrollment is 18-20 months.
Trial Details
NCT Number NCT06280950
Lead Sponsor National Institute of Allergy and Infectious Diseases (NIAID)
Conditions Liver Transplant
Enrollment 340 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov